High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing

Personalized Medicine

Volumn 5, Issue 3, 2008, Pages 225-232

  Ruaño, Gualberto ^a   Thompson, Paul D ^b   Villagra, David ^a   Bower, Bruce ^a   Kocherla, Mohan ^a   Yazdanpanah, Golriz ^a   Seip, Richard L ^a,b   Windemuth, Andreas ^a   White, C Michael ^b   Duconge, Jorge ^c   Holford, Theodore R ^d   Wu, Alan H B ^e  

^a Genomas Inc   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse drug reaction; Coumadin ; CYP2C9; Genotyping; Personalized medicine; Single nucleotide polymorphisms; VKORC1; Warfarin

Indexed keywords

ADENINE; CYTOCHROME P450 2C9; GUANINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENETIC ALGORITHM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; SEROPREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED STATES;

EID: 45149100367     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.5.3.225     Document Type: Article

References (43)

1. The top 200 generic drugs in 2006 (by units). Drug Topics 151, 25 (2007).
2. Couris R, Tataronis G, McCloskey W et al.: Dietary vitamin K variability affects International normalized ratio (INR) coagulation indices. Int. J. Vitam. Nutr. Res. 76, 65-74 (2006).
3. Hylek EM: Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin. Geriatr, Med. 17, 1-13 (2001).
4. Absher RK, Moore ME, Parker MH: Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother. 36, 1512-1517 (2002).
5. Kamali F, Pirmohamed M: The future prospects of pharmacogenetics in oral anticoagulation therapy. Br. J. Clin. Pharmacol. 61, 746-751 (2006).
6. Linder MW, Looney S, Adams JE III et al.: Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb. Thrombolysis 14, 227-232 (2002).
7. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 3942 (1994).
8. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72, 702-710 (2002).
9. Voora D, Eby C, Linder MW et al.: Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93, 700-705 (2005).
10. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
11. Reynolds KK, Valdes R Jr, Hartung BR, Linder MW: Individualizing warfarin therapy. Personalized Med. 4, 11-31 (2007).
12. Zhu Y, Sherman M, Reynolds KK et al.: Estimation of warfarin maintenance dose based on WORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53, 1199-1205 (2007).
13. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
14. Wu AH: Use of genetic and nongenetic factors in wartarin dosing algorithms. Pharmacogenomics 8, 851-861 (2007).
15. Mushiroda T, Ohnishi Y, Saito S et al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet. 51, 249-253 (2006).
16. Wadelius M, Sorlin K, Wallerman O et al.: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 4, 40-48 (2004).
17. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
18. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
19. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK: Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14, 539-547 (2004).
20. Rost S, Fregin A, Ivaskevicius V et al.: Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency Type 2. Nature 427, 537-541 (2004).
21. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW: Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
22. Suttie JW: The biochemical basis of warfarin therapy. Adv. Exp. Med. Biol. 214, 3-16 (1987).
23. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
24. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
25. Bristol-Myers Squibb Pharma Company: Cournadin Label. Bristol-Myers Squibb Pharma Company Princeton, NJ, USA, August 16, (2007).
26. Linkins LA, Choi PT, Douketis JD: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis. Ann. Intern. Med. 139, 893-900 (2003).
27. McWilliam A, Lutter R, Nardinelli C: Health-care savings from personalized medicine using genetic testing: the case of warfari. Working Paper 06-23. AE1-Brookings Joint Center for Regulatory Studies (2006).
28. Rosenberg Y: Rationale and outline of an NHLB/NIH Initiative for a large, multicenter randomized trial of genotype-guided dosage of warfarin therapy. Slide presentation from the NHLB/NIH workshop (2006).
29. Ruano G, Thompson PD, Windemuth A et al.: Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 865-872 (2005).
30. Gordon J, Merante F, Weiss S, Zastawny R: Pharmacogenetic P-450 screening using the Tag-it universal bead-based array platform. In: Pharmacogenomic and Proteomics: Enabling The Pactice of Personalized Medicine. Wong SH, Linder MW, Valdes R, (Eds). AAC Press, Washington, DC, USA (2006).
31. Schalekamp T, Brasse BP, Roijers JF et al.: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 80, 13-22 (2006).
32. Schwarz UI, Stein CM: Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin. Pharmacol. Ther. 80, 7-12 (2006).
33. Caldwell MD, Berg RL, Zhang KQ et al.: Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5, 8-16 (2007).
34. Sanderson S, Emery J, Fliggins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7. 97-104 (2005).
35. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. 78, 540-550 (2005).
36. Limdi NA, McGwin G, Goldstein JA et al.: Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on Warfarin. Clin. Pharmacol. Ther. 83, 312-320 (2007).
37. Gage BF, Lesko LJ: Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 25, 45-51 (2007).
38. Visser LE, van Vliet M, van Schaik RH et al.: The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14, 27-33 (2004).
39. Margaglione M, Colaizzo D, D'Andrea G et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84, 775-778 (2000).
40. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96, 1816-1819 (2000).
41. Veenstra DL, You JH, Rieder MJ et al.: Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
42. Cho HJ, Sohn KH, Park HM et al.: Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Phamacogenomics 8, 329-337 (2007).
43. Ruano G: Quo Vadis personalized medicine? Personalized Med. 1, 1-7 (2004).